Kymera Therapeutics (KYMR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kymera Therapeutics

NasdaqGM•Healthcare•Biotechnology

$116.33+3.18(0.03%)Pre-market

Market Cap

$11.60B

P/S

110.5x

P/B

7.7x

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How this company scores

AverageMetricSide Score: 43/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (7/25).

Profitability7/25

Growth13/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 110.5x5y range 17.3x – 179.4x

Currently above its 20-quarter median.

P/B · 7.7x5y range 2.1x – 7.7x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $11.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $105.00M
Q. Revenue: $65.00M
TTM EBITDA: $-337.71M
TTM Op. Income: $-350.18M
Q. Op. Income: $-75.61M
TTM Net Income: $-299.60M
Q. Net Income: $-61.21M
EPS: $-0.62
Shares Out.: $98.18M

$105.00M in TTM revenue grew 134.8% YoY, reaching $65.00M last quarter. TTM EBITDA of $-337.71M and TTM operating income of $-350.18M show growth is flowing through to the bottom line. However, net income is negative at $299.60M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 0.0%
EBITDA Margin: -113.2%
Op. Margin: -116.3%
Net Margin: -94.2%

Op. margin of -116.3% is up 620.5% YoY — cost efficiency is improving. Net margin at -94.2% and gross margin of 0.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 110.5x
P/B Ratio: 7.7x

P/S of 110.5x and P/B of 7.7x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.65B
Cash: $124.48M
Long-Term Debt: N/A
Book Value: $1.51B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-54.06M
TTM Free Cash Flow: $-237.96M
FCF Margin: -226.6%
FCF / Net Income: 0.8

TTM FCF of $-237.96M on $-54.06M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 6% — an improving trend.